Verastem's quest to develop drugs that block cell signaling pathways that cancer stem cells need to survive hits a major milestone in mid-2013, when it launches a 350-patient clinical trial of a potential companion biomarker test for its investigative mesothelioma drug treatment.
Qiagen disclosed it is seeking the FDA's blessing for a lung cancer-drug companion diagnostic, a test designed to screen patients for whom Boehringer Ingelheim's investigational treatment might work.
The companion diagnostic trend continues--and Ventana Medical Systems is involved yet again. This morning, Seattle Genetics and Takeda's Millennium unit announced that they are working with the Roche company on a companion diagnostic test for use in a study involving Adcetris.
Personalized medicine has been a popular topic in medical device and biopharma circles as of late. One company that has long had its eye on this area is Genoptix Medical Laboratory.
Colorectal cancer is a growing disease burden in the U.S., with roughly 140,000 new cases being diagnosed each year, according to the National Cancer Institute . Ann Arbor, MI-based Everist Genomics, which we profiled in our 5 innovative Michigan companies report last year, is looking to combat the disease and allow doctors to find it early enough to help patients.
We've been hearing a lot about companion diagnostics lately--especially as to how they can help save the healthcare system money by identifying those patients who might respond to certain treatments.
Siemens ( $SI ) is taking a big step into the hot companion diagnostic arena. The company, which makes a wide range of products, has announced separate pacts with ViiV Healthcare and Tocagen related to
It's a vexing problem that certain drugs with enormous benefit can also carry significant health risk. Case in point: Some patients who take the multiple sclerosis drug Tysabri experience improved
Another week, another big personalized medicine partnership announcement from Ventana Medical Systems . This time, the Roche unit said it will be working with Bayer Pharma on a molecular companion
In its latest of a series of companion diagnostic announcements, Roche's Ventana unit says it is collaborating with Pfizer ( $PFE ) and Cell Signaling Technology (CST) to develop a test identifying